Immunocore (IMCR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

IMCR Stock Forecast

Immunocore stock forecast is as follows: an average price target of $70.20 (represents a 142.24% upside from IMCR’s last price of $28.98) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

IMCR Price Target

The average price target for Immunocore (IMCR) is $70.20 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $24.00. This represents a potential 142.24% upside from IMCR's last price of $28.98.

IMCR Analyst Ratings

Buy

According to 7 Wall Street analysts, Immunocore's rating consensus is 'Buy'. The analyst rating breakdown for IMCR stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Immunocore Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 24, 2024	David Dai	UBS	$24.00	$32.02	-25.05%	-17.18%
Sep 16, 2024	Justin Kim	Oppenheimer	$89.00	$33.05	169.29%	207.11%
Sep 12, 2024	Graig Suvannavejh	Mizuho Securities	$72.00	$33.44	115.31%	148.45%
Aug 28, 2024	Patrick Trucchio	H.C. Wainwright	$100.00	$35.71	180.03%	245.07%
Aug 09, 2024	Peter Lawson	Barclays	$66.00	$37.92	74.05%	127.74%
May 13, 2024	Graig Suvannavejh	Mizuho Securities	$88.00	$57.25	53.71%	203.66%
May 09, 2024	Bill Maughan	Canaccord Genuity	$67.00	$61.32	9.26%	131.19%
Dec 15, 2022	Rajan Sharma	Goldman Sachs	$80.00	$59.42	34.63%	176.05%
Sep 09, 2022	Michael Yee	Jefferies	$68.00	$44.03	54.43%	134.64%

The latest Immunocore stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $24.00, which represents a -25.05% decrease from the stock price at the time of the forecast ($32.02), and a -17.18% decrease from IMCR last price ($28.98).

Immunocore Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	7
Avg Price Target	-	$24.00	$72.29
Last Closing Price	$28.98	$28.98	$28.98
Upside/Downside	-100.00%	-17.18%	149.45%

In the current month, the average price target of Immunocore stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immunocore's last price of $28.98. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	Oppenheimer	Underperform	Underperform	Hold
Oct 24, 2024	UBS	Buy	Buy	Hold
Oct 24, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 24, 2024	UBS		Sell	Initialise
Oct 07, 2024	Needham	Underperform	Underperform	Hold
Oct 07, 2024	Oppenheimer	Buy	Buy	Hold
Oct 07, 2024	Guggenheim		Neutral	Downgrade
Sep 16, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 16, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 28, 2024	Oppenheimer	Buy	Buy	Hold
Aug 28, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 09, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Aug 09, 2024	Needham	Buy	Buy	Hold
Aug 09, 2024	Barclays	Overweight	Overweight	Hold
Jul 10, 2024	Leerink Partners	Underperform	Underperform	Hold
Jul 10, 2024	Needham	Buy	Buy	Hold
Jun 03, 2024	Cowen & Co.	Buy	Buy	Hold
May 24, 2024	Needham	Underperform	Underperform	Hold
May 24, 2024	Oppenheimer	Buy	Buy	Hold
May 09, 2024	H.C. Wainwright	Buy	Buy	Hold
May 09, 2024	Canaccord Genuity	Hold	Hold	Hold
Apr 29, 2024	Needham	Underperform	Underperform	Hold
Apr 29, 2024	Oppenheimer	Buy	Buy	Hold
Feb 29, 2024	Oppenheimer	Buy	Buy	Hold
Jan 05, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 13, 2023	Needham		Buy	Initialise
Dec 15, 2022	Goldman Sachs		Buy	Upgrade
Nov 30, 2022	Barclays		Overweight	Initialise

Immunocore's last stock rating was published by Oppenheimer on Oct 24, 2024. The company gave IMCR a "Underperform" rating, the same as its previous rate.

Immunocore Financial Forecast

Immunocore Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$105.64M	$51.49M	-	$44.54M	$48.06M	$41.20M	$32.00M	$22.47M	$6.59M	$5.92M	$5.73M	$8.27M	$7.42M
Avg Forecast	$91.86M	$93.20M	$92.95M	$92.44M	$92.14M	$90.23M	$88.21M	$86.10M	$84.51M	$78.94M	$74.58M	$69.47M	$66.58M	$62.79M	$57.76M	$49.51M	$52.20M	$37.39M	$20.97M	$8.34M	$7.79M	$7.36M	$7.83M	$11.47M	$6.46M
High Forecast	$107.94M	$109.52M	$109.22M	$108.62M	$108.26M	$106.02M	$103.64M	$91.42M	$88.13M	$92.75M	$87.63M	$81.62M	$76.67M	$73.78M	$67.87M	$58.18M	$61.34M	$37.39M	$20.97M	$8.34M	$7.79M	$7.36M	$7.83M	$11.47M	$6.46M
Low Forecast	$86.12M	$87.38M	$87.14M	$86.66M	$86.38M	$84.59M	$82.69M	$83.16M	$83.00M	$74.01M	$69.92M	$65.12M	$58.22M	$58.87M	$54.15M	$46.42M	$48.94M	$37.39M	$20.97M	$8.34M	$7.79M	$7.36M	$7.83M	$11.47M	$6.46M
# Analysts	3	3	3	3	4	4	4	6	10	9	5	10	11	5	5	9	5	4	4	7	5	5	10	7	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.59%	0.82%	-	0.90%	0.92%	1.10%	1.53%	2.69%	0.85%	0.81%	0.73%	0.72%	1.15%

Immunocore's average Quarter revenue forecast for Mar 24 based on 10 analysts is $69.47M, with a low forecast of $65.12M, and a high forecast of $81.62M. IMCR's average Quarter revenue forecast represents a -34.24% decrease compared to the company's last Quarter revenue of $105.64M (Dec 23).

Immunocore EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	3	3	3	3	4	4	4	6	10	9	5	10	11	5	5	9	5	4	4	7	5	5	10	7	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-37.54M	$14.06M	-	$-13.56M	$-19.90M	$-6.94M	$-12.02M	$-14.77M	$-36.11M	$-29.23M	$-32.71M	$-30.05M	$-17.60M
Avg Forecast	$-63.83M	$-64.76M	$-64.58M	$-64.22M	$-64.01M	$-62.69M	$-61.28M	$-59.82M	$-58.72M	$-54.85M	$-51.82M	$-48.26M	$-46.26M	$-43.63M	$-40.13M	$-34.40M	$-36.27M	$-25.48M	$-14.29M	$-15.89M	$-5.31M	$-5.02M	$-5.34M	$-19.39M	$-4.40M
High Forecast	$-59.84M	$-60.71M	$-60.54M	$-60.21M	$-60.01M	$-58.77M	$-57.45M	$-57.78M	$-57.67M	$-51.42M	$-48.58M	$-45.25M	$-40.45M	$-40.90M	$-37.62M	$-32.25M	$-34.00M	$-25.48M	$-14.29M	$-12.71M	$-5.31M	$-5.02M	$-5.34M	$-15.51M	$-4.40M
Low Forecast	$-74.99M	$-76.09M	$-75.88M	$-75.46M	$-75.22M	$-73.66M	$-72.01M	$-63.52M	$-61.23M	$-64.44M	$-60.89M	$-56.71M	$-53.27M	$-51.26M	$-47.15M	$-40.42M	$-42.62M	$-25.48M	$-14.29M	$-19.06M	$-5.31M	$-5.02M	$-5.34M	$-23.26M	$-4.40M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.81%	-0.32%	-	0.39%	0.55%	0.27%	0.84%	0.93%	6.80%	5.83%	6.13%	1.55%	4.00%

11 analysts predict IMCR's average Quarter EBITDA for Dec 23 to be $-46.26M, with a high of $-40.45M and a low of $-53.27M. This is -429.08% lower than Immunocore's previous annual EBITDA (Sep 23) of $14.06M.

Immunocore Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	3	3	3	3	4	4	4	6	10	9	5	10	11	5	5	9	5	4	4	7	5	5	10	7	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-26.42M	$1.90M	-	$-16.70M	$-25.20M	$6.23M	$-6.12M	$-16.13M	$-39.39M	$-30.13M	$-32.96M	$-29.04M	$-18.88M
Avg Forecast	$-8.32M	$-6.66M	$-5.41M	$-3.75M	$-17.68M	$-14.20M	$-12.24M	$-11.01M	$-9.72M	$-13.54M	$-19.86M	$-15.48M	$-10.35M	$-15.26M	$-16.24M	$-14.86M	$1.14M	$-12.59M	$-30.17M	$-17.35M	$-39.90M	$-41.60M	$-34.97M	$-18.73M	$-39.00M
High Forecast	$-7.65M	$-6.12M	$-4.97M	$-3.44M	$-16.24M	$-13.05M	$-11.25M	$-3.26M	$-2.13M	$-12.44M	$-18.24M	$-14.22M	$-2.59M	$-14.02M	$-14.92M	$-13.65M	$1.40M	$-12.59M	$-30.17M	$-13.88M	$-39.90M	$-41.60M	$-34.97M	$-14.99M	$-39.00M
Low Forecast	$-10.22M	$-8.17M	$-6.64M	$-4.60M	$-21.70M	$-17.44M	$-15.03M	$-17.13M	$-22.05M	$-16.62M	$-24.37M	$-19.00M	$-17.75M	$-18.73M	$-19.93M	$-18.24M	$1.05M	$-12.59M	$-30.17M	$-20.82M	$-39.90M	$-41.60M	$-34.97M	$-22.48M	$-39.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	2.55%	-0.12%	-	1.12%	-22.09%	-0.49%	0.20%	0.93%	0.99%	0.72%	0.94%	1.55%	0.48%

Immunocore's average Quarter net income forecast for Dec 23 is $-10.35M, with a range of $-17.75M to $-2.59M. IMCR's average Quarter net income forecast represents a -643.84% decrease compared to the company's last Quarter net income of $1.90M (Sep 23).

Immunocore SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	3	3	3	3	4	4	4	6	10	9	5	10	11	5	5	9	5	4	4	7	5	5	10	7	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$64.19M	$10.99M	-	$33.30M	$43.14M	$25.88M	$24.51M	$20.11M	$24.37M	$20.05M	$23.80M	$20.18M	$14.17M
Avg Forecast	$143.40M	$145.49M	$145.09M	$144.29M	$143.82M	$140.85M	$137.68M	$134.39M	$131.92M	$123.22M	$116.42M	$108.43M	$103.94M	$98.02M	$90.16M	$77.29M	$81.49M	$58.37M	$32.73M	$13.02M	$12.15M	$11.49M	$12.23M	$17.90M	$10.08M
High Forecast	$168.49M	$170.95M	$170.48M	$169.54M	$168.99M	$165.50M	$161.78M	$142.71M	$137.57M	$144.79M	$136.79M	$127.41M	$119.68M	$115.17M	$105.94M	$90.81M	$95.75M	$58.37M	$32.73M	$13.02M	$12.15M	$11.49M	$12.23M	$17.90M	$10.08M
Low Forecast	$134.43M	$136.39M	$136.02M	$135.27M	$134.83M	$132.05M	$129.08M	$129.81M	$129.56M	$115.52M	$109.14M	$101.65M	$90.89M	$91.89M	$84.53M	$72.46M	$76.39M	$58.37M	$32.73M	$13.02M	$12.15M	$11.49M	$12.23M	$17.90M	$10.08M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.62%	0.11%	-	0.43%	0.53%	0.44%	0.75%	1.54%	2.00%	1.75%	1.95%	1.13%	1.41%

Immunocore's average Quarter SG&A projection for Mar 24 is $108.43M, based on 10 Wall Street analysts, with a range of $101.65M to $127.41M. The forecast indicates a 68.91% rise compared to IMCR last annual SG&A of $64.19M (Dec 23).

Immunocore EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	3	3	3	3	4	4	4	6	10	9	5	10	11	5	5	9	5	4	4	7	5	5	10	7	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$0.04	-	$-0.35	$-0.54	$0.13	$-0.14	$-0.37	$-0.90	$-0.69	$-0.75	$-0.76	$-0.49
Avg Forecast	$-0.16	$-0.13	$-0.10	$-0.07	$-0.33	$-0.27	$-0.23	$-0.21	$-0.18	$-0.26	$-0.38	$-0.29	$-0.20	$-0.29	$-0.31	$-0.28	$0.02	$-0.25	$-0.60	$-0.84	$-0.80	$-0.83	$-0.70	$-0.60	$-0.78
High Forecast	$-0.14	$-0.12	$-0.09	$-0.07	$-0.31	$-0.25	$-0.21	$-0.06	$-0.04	$-0.24	$-0.35	$-0.27	$-0.05	$-0.27	$-0.28	$-0.26	$0.03	$-0.25	$-0.60	$-0.84	$-0.80	$-0.83	$-0.70	$-0.60	$-0.78
Low Forecast	$-0.19	$-0.15	$-0.13	$-0.09	$-0.41	$-0.33	$-0.28	$-0.32	$-0.42	$-0.31	$-0.46	$-0.36	$-0.34	$-0.35	$-0.38	$-0.35	$0.02	$-0.25	$-0.60	$-0.84	$-0.80	$-0.83	$-0.70	$-0.60	$-0.78
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	-0.14%	-	1.24%	-24.99%	-0.52%	0.23%	0.44%	1.13%	0.83%	1.07%	1.27%	0.63%

According to 11 Wall Street analysts, Immunocore's projected average Quarter EPS for Dec 23 is $-0.20, with a low estimate of $-0.34 and a high estimate of $-0.05. This represents a -590.20% decrease compared to IMCR previous annual EPS of $0.04 (Sep 23).

Immunocore Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$2.37	$33.86	1328.69%	Buy
LRMR	Larimar Therapeutics	$4.32	$17.00	293.52%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
KALV	KalVista Pharmaceuticals	$8.65	$22.67	162.08%	Buy
IMCR	Immunocore	$29.40	$70.20	138.78%	Buy
ERAS	Erasca	$2.63	$6.00	128.14%	Buy
PCVX	Vaxcyte	$89.86	$148.80	65.59%	Buy
DSGN	Design Therapeutics	$6.25	$9.67	54.72%	Buy
ACLX	Arcellx	$82.03	$111.60	36.05%	Buy
MIRM	Mirum Pharmaceuticals	$42.65	$57.00	33.65%	Buy
NUVL	Nuvalent	$88.10	$114.80	30.31%	Buy
VRDN	Viridian Therapeutics	$20.82	$22.75	9.27%	Buy

IMCR Forecast FAQ

Is Immunocore a good buy?

Yes, according to 7 Wall Street analysts, Immunocore (IMCR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of IMCR's total ratings.

What is IMCR's price target?

Immunocore (IMCR) average price target is $70.2 with a range of $24 to $100, implying a 142.24% from its last price of $28.98. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Immunocore stock go up soon?

According to Wall Street analysts' prediction for IMCR stock, the company can go up by 142.24% (from the last price of $28.98 to the average price target of $70.2), up by 245.07% based on the highest stock price target, and down by -17.18% based on the lowest stock price target.

Can Immunocore stock reach $40?

IMCR's average twelve months analyst stock price target of $70.2 supports the claim that Immunocore can reach $40 in the near future.

What are Immunocore's analysts' financial forecasts?

Immunocore's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $356.67M (high $409.35M, low $336.82M), average EBITDA is $-248M (high $-234M, low $-284M), average net income is $-55.14M (high $-43.803M, low $-71.297M), average SG&A $556.75M (high $638.97M, low $525.77M), and average EPS is $-1.044 (high $-0.829, low $-1.35). IMCR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $370.46M (high $435.29M, low $347.3M), average EBITDA is $-257M (high $-241M, low $-302M), average net income is $-24.142M (high $-22.18M, low $-29.634M), average SG&A $578.27M (high $679.46M, low $542.12M), and average EPS is $-0.457 (high $-0.42, low $-0.561).

Did the IMCR's actual financial results beat the analysts' financial forecasts?

Based on Immunocore's last annual report (Dec 2023), the company's revenue was $249.43M, beating the average analysts forecast of $236.65M by 5.40%. Apple's EBITDA was $-59.649M, missing the average prediction of $-164M by -63.72%. The company's net income was $-55.287M, missing the average estimation of $-56.709M by -2.51%. Apple's SG&A was $144.5M, missing the average forecast of $369.4M by -60.88%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-1.074 by -99.90%. In terms of the last quarterly report (Dec 2023), Immunocore's revenue was $105.64M, beating the average analysts' forecast of $66.58M by 58.65%. The company's EBITDA was $-37.543M, missing the average prediction of $-46.262M by -18.85%. Immunocore's net income was $-26.417M, beating the average estimation of $-10.355M by 155.12%. The company's SG&A was $64.2M, missing the average forecast of $103.94M by -38.24%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.196 by -99.75%